Procore stock price target raised to $90 from Goldman Sachs on stabilizing growth
Investing.com - Canaccord Genuity maintained its Buy rating and $20.00 price target on Biodesix (NASDAQ:BDSX) following the company’s better-than-expected third-quarter 2025 results released Monday. This target represents significant upside potential from the current price of $6.34, with analysts across the board showing optimism through a strong consensus recommendation of 1.4.
The lung diagnostic specialist reported quarterly results that exceeded both Canaccord’s estimates and FactSet consensus, showing modest quarter-over-quarter growth in test volumes and revenue. The company attributed part of this improvement to better average selling prices resulting from improved payer dynamics, with approximately 11% of test volume coming from primary care. This performance continues Biodesix’s strong revenue growth trajectory, which stands at 25.7% over the last twelve months, with revenues reaching $76.56 million.
Biodesix continues to make progress on its commercial restructuring, currently employing 85 sales representatives with plans to reach 93-97 representatives by the end of 2025. The company also highlighted interim CLARIFY study results presented at the recent CHEST conference. Despite maintaining a healthy current ratio of 2.14, InvestingPro data shows Biodesix is operating with significant debt of $73.47 million and is not yet profitable, with an EBITDA of -$28.08 million.
Following the strong quarterly performance, Biodesix raised its full-year 2025 revenue guidance while reaffirming its target to achieve positive adjusted EBITDA in the fourth quarter of 2025.
Canaccord noted that disruption from the company’s strategic shift appears to be stabilizing, and believes Biodesix’s focus on pulmonology and primary care markets positions it for long-term revenue growth, making the stock attractive at current levels.
In other recent news, Biodesix Inc . reported its third-quarter 2025 earnings, which revealed a significant miss on its earnings per share (EPS) forecast. The company posted an EPS of -$1.16, which was far below the forecasted -$0.06, marking a substantial surprise of 1833.33%. Despite the EPS miss, Biodesix’s revenue surpassed expectations, reaching $21.8 million compared to the forecasted $20.83 million, a 4.66% surprise. These recent developments have drawn attention from investors and analysts alike. The earnings report underscores the importance of closely monitoring both earnings and revenue figures. While the revenue beat might offer some encouragement, the EPS miss highlights challenges the company faces. Investors are advised to keep an eye on further announcements from Biodesix for any potential strategic changes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.